Coffee and Tea on Cardiovascular Disease (CVD) prevention

2021 ◽  
Author(s):  
David Chieng ◽  
Peter M Kistler
Keyword(s):  
Cardiovascular Disease ◽  
Cvd Prevention

Impact of following a healthy dietary pattern with co-consuming wolfberry on number and function of blood outgrowth endothelial cells from middle-aged and older adults

2021 ◽  
Author(s):  
Xuejuan Xia ◽  
Darel Wee Kiat Toh ◽  
Shi Ling Ng ◽  
Olga Zharkova ◽  
Kian Keong Poh ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Older Adults ◽  
Endothelial Cells ◽  
Dietary Pattern ◽  
Middle Aged ◽  
Diet Intervention ◽  
Cvd Prevention ◽  
And Function ◽  
Healthy Dietary Pattern ◽  
Primary Strategy

Blood outgrowth endothelial cells (BOECs) have received growing attention in relation to the cardiovascular disease (CVD). However, the effect of diet intervention, a primary strategy for CVD prevention on BOECs...

Diabetic dyslipidaemia

2011 ◽  
pp. 1963-1969
Author(s):  
John Betteridge
Keyword(s):  
Cardiovascular Disease ◽  
Practical Approach ◽  
Cvd Risk ◽  
Diagnosis And Management ◽  
Cvd Prevention ◽  
Multifactorial Approach ◽  
Lipoprotein Disorders

Management of dyslipidaemia is an integral part of the multifactorial approach to cardiovascular disease (CVD) prevention in people with diabetes. In this chapter the pathogenesis of lipid and lipoprotein disorders in diabetes and their relationship to CVD risk will be discussed together with a practical approach to diagnosis and management.

scholarly journals Anxiety and new onset of cardiovascular disease: critical review and meta-analysis

2016 ◽  
Vol 208 (3) ◽  
pp. 223-231 ◽  
Author(s):  
Neeltje M. Batelaan ◽  
Adrie Seldenrijk ◽  
Mariska Bot ◽  
Anton J. L. M. van Balkom ◽  
Brenda W. J. H. Penninx
Keyword(s):  
Cardiovascular Disease ◽  
Meta Analysis ◽  
Population Based ◽  
Future Research ◽  
Cvd Prevention ◽  
Traditional Risk Factors ◽  
Independent Association ◽  
New Onset

BackgroundAnxiety has been associated with new-onset cardiovascular disease (CVD), but the quality of this relationship is unclear. Only if anxiety is a causal, independent cardiovascular risk factor might it be a target for CVD prevention.AimsTo determine and examine the independent association and causality between anxiety and incident CVD.MethodPubMed, EMBASE and PsycINFO databases were searched up to October 2013. A review of Hill's criteria for causality and random effects meta-analysis were conducted of prospective, population-based studies examining anxiety and incident CVD in people free from CVD at baseline.ResultsThe meta-analysis comprised 37 papers (n= 1 565 699). The follow-up ranged from 1 to 24 years. Anxiety was associated with a 52% increased incidence of CVD (hazard ratio = 1.52, 95% CI 1.36–1.71). The risk seemed independent of traditional risk factors and depression. The evaluation of Hill's criteria largely argued in favour of causality.ConclusionsAnxiety may be of interest for CVD prevention. Future research should examine biological and behavioural underpinnings of the association in order to identify targets for intervention.

scholarly journals Daily Almond Consumption in Cardiovascular Disease Prevention via LDL-C Change in the U.S. Population: a Cost-Effectiveness Analysis

2019 ◽  
Author(s):  
Jifan Wang(New Corresponding Author) ◽  
Michelle A. Lee Bravatti ◽  
Elizabeth J. Johnson ◽  
Gowri Raman(Former Corresponding Author)
Keyword(s):  
Cardiovascular Disease ◽  
Cost Effectiveness ◽  
Willingness To Pay ◽  
Cost Effective ◽  
Dietary Factors ◽  
Sensitivity Analyses ◽  
Healthcare Sector ◽  
Cvd Prevention ◽  
The Cost ◽  
The U.S

Abstract Objectives Heart disease is the leading cause of death in the United States. The U.S. Food and Drug Administration approved the health claim that 1.5 ounces (42.5 grams) of nut intake may reduce the risk of cardiovascular disease (CVD). Previous studies have focused on the cost-effectiveness of other foods or dietary factors on primary CVD prevention, yet not in almond consumption. This study aimed to examine the cost-effectiveness of almond consumption in CVD primary prevention. Perspective & Setting This study assessed the cost-effectiveness of consuming 42.5 grams of almond from the U.S. healthcare sector perspective. Methods A decision model was developed for 42.5 grams of almond per day versus no almond consumption and CVD in the U.S. population. Parameters in the model were derived from the literature, which included the probabilities of increasing LDL-C, developing acute myocardial infarction (MI) and stroke, treating MI, dying from the disease and surgery, as well as the costs of the disease and procedures in the U.S. population, and the quality-adjusted life years (QALY). The cost of almonds was based on the current price in the U.S. market. Sensitivity analyses were conducted for different levels of willingness-to-pay, the probabilistic sensitivity analysis, ten-year risk prevention, different costs of procedures and almond prices, and patients with or without CVD. Results The almond strategy had $363 lower cost and 0.02 higher QALY gain compared to the non-almond strategy in the base-case model. The annual net monetary benefit (NMB) of almond consumption was $1,421 higher per person than no almond consumption, when the willingness to pay threshold was set at $50,000 for annual health care expenditure. Almond was more cost-effective than non-almond in CVD prevention in all the sensitivity analyses. Conclusion Consuming 42.5 grams of almonds per day is a cost-effective approach to prevent CVD in the short term and potentially in the long term.

scholarly journals Knowledge and Perceptions towards Cardiovascular Disease Prevention among Patients with Type 2 Diabetes Mellitus: A Review of Current Assessments and Recommendations

2020 ◽  
Vol 16 ◽  
Author(s):  
Mohamed Hassan Elnaem ◽  
Mahmoud E Elrggal ◽  
Nabeel Syed ◽  
Atta Abbas Naqvi ◽  
Muhammad Abdul Hadi
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 2 Diabetes Mellitus ◽  
Original Research ◽  
Knowledge Gaps ◽  
Cvd Risk ◽  
Cvd Prevention

Introduction: Patients with type 2 diabetes mellitus (T2DM) are at significantly higher risk of developing cardiovascular disease (CVD). There is scarcity of literature reviews that describes and summarises T2DM patients' knowledge and perception about CVD prevention. Objectives: To describe and summarise the assessment of knowledge and perceptions about CVD risk and preventive approaches among patients with T2DM. Methods: A scoping review methodology was adopted, and three scientific databases, Google Scholar, Science Direct and PubMed were searched using predefined search terms. A multistage screening process that considered relevancy, publication year (2009-2019), English language, and article type (original research) was followed. We formulated research questions focused on the assessment of levels of knowledge and perceptions of the illness relevant to CVD prevention and the identification of associated patients' characteristics. Results: A total of 16 studies were included. Patients were not confident to identify CVD risk and other clinical consequences that may occur in the prognostic pathway of T2DM. Furthermore, patients were less likely to identify all CV risk factors indicating a lack of understanding of the multi-factorial contribution of CVD risk. Patients' beliefs about medications were correlated with their level of adherence to medications for CVD prevention. Many knowledge gaps were identified, including the basic disease expectations at the time of diagnosis, identification of individuals' CVD risk factors and management aspects. Knowledge and perceptions were affected by patients' demographic characteristics, e.g., educational level, race, age, and area of residence. Conclusion: There are knowledge gaps concerning the understanding of CVD risk among patients with T2DM. The findings necessitate educational initiatives to boost CVD prevention among patients with T2DM. Furthermore, these should be individualised based on patients' characteristics and knowledge gaps, disease duration and estimated CVD risk.

scholarly journals JUSTIFICATION OF A SYSTEMIC APPROACH IN THE SUDDEN CARDIAC DEATH PREVENTION: A POSSIBLE SOLUTION TO THE PROBLEM OF EXCESSIVE MORTALITY IN RUSSIA (LITERATURE REVIEW) PART I. CARDIOVASCULAR ASPECTS OF EXCESSIVE MORALITY IN RUSSIA: THE STATE OF THE PROBLEM AND POTENTIAL FOR PREVENTION

2013 ◽  
Vol 12 (2) ◽  
pp. 98-104
Author(s):  
A. S. Dimov ◽  
N. I. Maksimov
Keyword(s):  
Cardiovascular Disease ◽  
Sudden Cardiac Death ◽  
Literature Review ◽  
Cardiac Death ◽  
Large Scale ◽  
The State ◽  
Systemic Approach ◽  
Initial Stage ◽  
Cvd Prevention ◽  
Healthcare Situation

The review of the existing evidence on the problem of excessive mortality in Russia has demonstrated that the country is at the initial stage of the irreversible depopulation process. The current healthcare situation, in regard to cardiovascular disease (CVD), does not provide much hope for the effectiveness of existing measures for fatal CVD prevention. It is clear that a large-scale focussed analysis of the clinical and organisational limitations of the existing prevention systems is urgently needed. This discussion should be started in the nearest future. 

scholarly journals Lifelong prevention of cardiovascular disease. Part I: preconceptional, prenatal and infant periods of life

2020 ◽  
Vol 19 (6) ◽  
pp. 2647
Author(s):  
O. V. Kopylova ◽  
A. I. Ershova ◽  
A. N. Meshkov ◽  
O. M. Drapkina
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
Preventive Measures ◽  
Cumulative Effect ◽  
Life Stages ◽  
Beneficial Effects ◽  
Cvd Prevention ◽  
Prevention Of Cardiovascular Disease

Current prophylactic actions prevent or significantly delay the majority of cardiovascular diseases (CVD). Various factors are interconnected and affect a person throughout his life, determining the risk of CVD. This indicates the need for preventive measures at all stages of life and even before birth. The beneficial effects of CVD prevention are realized through various genetic, epigenetic and metabolic mechanisms. Due to the fact that many risk factors for CVD have a cumulative effect, the introduction of preventive measures from the earliest life stages will be most effective. The purpose of the article is to consider various aspects of CVD prevention in the preconceptional, prenatal and infant periods.

Micro-simulation model to predict effects of low-dose aspirin on colorectal cancer, cardiovascular disease and safety outcomes among low-dose aspirin users

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
K Bollaerts ◽  
J Biccler ◽  
V Pareen ◽  
E Sole ◽  
L.A Garcia Rodriguez ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cardiovascular Disease ◽  
Simulation Model ◽  
Low Dose ◽  
Funding Source ◽  
Peptic Ulcers ◽  
Gi Bleeding ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Cvd Prevention

Abstract Background Regular use of low-dose aspirin (LDA) has been shown to reduce the risk of cardiovascular disease (CVD). Recent evidence indicates that regular LDA use also reduces the risk of colorectal cancer (CRC). Use of LDA has also been associated with an increased risk of gastrointestinal (GI) bleeding, peptic ulcers and intracranial hemorrhage (ICH). Purpose We aim to evaluate the population-level benefits and risks of daily and/or regular LDA among individuals taking LDA for primary or secondary CVD prevention in the United Kingdom (UK) accounting for the evidence on the reduced CRC risk. Methods Individual-level state transition modelling was used to predict the impact of LDA on CRC, CVD, safety events (GI bleeding, ICH and symptomatic peptic ulcers) and related deaths in a UK population. Individual event histories were simulated for hypothetical cohorts of 1 million adults aged 50–59 years and aged 60–69 years indicated to take LDA for primary or secondary CVD prevention. The QRISK CVD prediction score was used to simulate adults indicated to use LDA for CVD prevention. Model parameters were informed based on published scientific literature on CVD, CRC and safety outcomes mimicking the UK epidemiology and prevention guidelines. Monte Carlo simulation was used to account for parameter uncertainty. Results In the cohort of subjects for which low-dose aspirin use was initiated between 50–59 years, the decrease in incidence rates (IRs) (per 100,000person years) of non-fatal CVD was smaller when low-dose aspirin use was initiated for primary prevention compared to initiation for secondary prevention (−203 [95% UI, −277 to −115] versus −794 [95% UI, −997 to −536]). Similar results were obtained for fatal CVD (−97 [95% UI, −136 to −60] versus −381 [95% UI, −502 to −257]). Whether low-dose aspirin treatment was initiated for primary or secondary CVD prevention did not greatly influence the changes in the IR of the non-CVD outcomes. The changes in IR for fatal CRC were −46 [−69, −31] and −44 [−67, −26] for primary and secondary CVD prevention while the changes in IR for fatal bleeding were 5 [1, 9] and 5 [1, 10]. Similar results were obtained when low-dose aspirin use was initiated between 60–69 years. Conclusions In all simulation settings considered, low-dose aspirin related reductions in non-fatal and fatal CVD outcomes were larger in case of secondary CVD prevention compared to primary CVD prevention. These reductions were larger than the increases in fatal safety events. This favorable benefit-risk profile is more pronounced in the case of secondary CVD prevention. The results from the simulation model can be used to inform discussions with patients about the potential benefits and risk of LDA initiation. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Bayer AG

scholarly journals The Legacy Effect in the Prevention of Cardiovascular Disease

Nutrients ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3227
Author(s):  
Esther Viñas Esmel ◽  
José Naval Álvarez ◽  
Emilio Sacanella Meseguer
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Preventive Treatment ◽  
Patient Characteristics ◽  
Dietary Interventions ◽  
Recent Onset ◽  
Legacy Effect ◽  
Cvd Prevention

The “legacy effect” describes the long-term benefits that may persist for many years after the end of an intervention period, involving different biological processes. The legacy effect in cardiovascular disease (CVD) prevention has been evaluated by a limited number of studies, mostly based on pharmacological interventions, while few manuscripts on dietary interventions have been published. Most of these studies are focused on intensive treatment regimens, whose main goal is to achieve tight control of one or more cardiovascular risk factors. This review aims to summarise the legacy effect-related results obtained in those studies and to determine the existence of this effect in CVD prevention. There is sufficient data to suggest the existence of a legacy effect after intensive intervention on cardiovascular risk factors; however, this effect is not equivalent for all risk factors and could be influenced by patient characteristics, disease duration, and the type of intervention performed. Currently, available evidence suggests that the legacy effect is greater in subjects with moderately-high cardiovascular risk but without CVD, especially in those patients with recent-onset diabetes. However, preventive treatment for CVD should not be discontinued in high-risk subjects, as the level of existing evidence on the legacy effect is low to moderate.

Sign in / Sign up

Export Citation Format

Share Document